Fleet Laboratories
Fleet Laboratories Ltd are part of the DDD Group of Companies which was established in 1912 and is still privately owned. We work with customers in the health and beauty industry manufacturing pharmaceutical products on behalf of the licence holder and developing and manufacturing toiletry products for both brand owners and retailers. We have a diverse range of customers, some of whom we have worked with for nearly 30 years. Depending on your business need, we have a flexible range of services available.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
Company Details
Latest Content from PMHub
AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation
Press Releases | September 17, 2025 | Innovative Trials
Kate Shaw comments on the latest news about AstraZeneca and Merck's decision to hold planned investments in the UK
Lucid Strategy Consulting: Empowering Next-Generation Solutions for Life Sciences
Press Releases | September 16, 2025 | Lucid Group Communications Limited
Lucid Group announces the evolution of its consulting division, Lucid Strategy Consulting, setting a new standard for deep-domain, knowledge-led consulting solutions for life sciences. We have brought together two Lucid...
Streamlining European expansion for cell and gene therapies
White Papers and Resources | September 16, 2025 | Uniphar
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe...
Current CGT landscape and future outlook
White Papers and Resources | September 16, 2025 | Uniphar
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer...
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
White Papers and Resources | September 16, 2025 | Uniphar
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of...
Navigating the complexities of launch preparation for Cell and Gene Therapy
White Papers and Resources | September 16, 2025 | Uniphar
Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients...
Virtual Practice, Real Results: The Power of Virtual Patient Simulation
Press Releases | September 15, 2025 | Medscape Education
Simulation has never been more vital in medicine than it is today. As increasing numbers of physicians turn to large language models for clinical answers1, the real differentiator isn’t just...
A New Destination for Oncology Education
Press Releases | September 15, 2025 | Medscape Education
Medscape Oncology is pleased to announce the launch of a groundbreaking new learning space designed to provide education across tumor types and oncology disciplines: PIONEER – PrecIsion Oncology: Navigating EvidEnce...
A Call to Action: Bridging the Adult Immunization Divide
Press Releases | September 12, 2025 | Medscape Education
Over the past few years, as new diseases have emerged or reemerged, a host of new vaccines have become available while many others are in the pipeline. For older adults,...
ISPOR hosts expert webinar exploring the value of ECAs for regulatory and HTA evidence needs
Press Releases | September 12, 2025 | Genesis Research Group
On Tuesday, October 7th, you are invited to join a Genesis Research Group-led webinar exploring the value of External Control Arm (ECA) studies. Gaining traction as part of evidence generation...